ahlam1399
04-08-2016, 07:33 PM
FDA staff questions Clovis drug?s benefit over current treatments
(Reuters) - The U.S. Food and Drug Administration staff reviewers on Friday questioned whether Clovis Oncology Inc's lung cancer drug was superior to existing treatments.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ecf9a4d/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=IPHvIatXPY4:VGqiB-qdXow:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=IPHvIatXPY4:VGqiB-qdXow:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/IPHvIatXPY4
(Reuters) - The U.S. Food and Drug Administration staff reviewers on Friday questioned whether Clovis Oncology Inc's lung cancer drug was superior to existing treatments.
http://i2.wp.com/reuters.us.feedsportal.com/c/35217/f/654207/s/4ecf9a4d/sc/14/mf.gif?resize=1%2C1http://feeds.feedburner.com/~ff/reuters/healthNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:yIl2AUoC8zA) http://feeds.feedburner.com/~ff/reuters/healthNews?i=IPHvIatXPY4:VGqiB-qdXow:F7zBnMyn0Lo (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:F7zBnMyn0Lo) http://feeds.feedburner.com/~ff/reuters/healthNews?i=IPHvIatXPY4:VGqiB-qdXow:V_sGLiPBpWU (http://feeds.reuters.com/~ff/reuters/healthNews?a=IPHvIatXPY4:VGqiB-qdXow:V_sGLiPBpWU)
http://feeds.feedburner.com/~r/reuters/healthNews/~4/IPHvIatXPY4